| Total n = 182 | E. faecalis n = 144 | E. faecium n = 38 |
---|---|---|---|
Age, mean (SD), years | 64.6 (18.2) | 65.0 (19.3) | 64.8 (13.5) |
Male sex n, (%) | 114 (62.6) | 89 (61.8) | 25 (65.8) |
Type of infection n, (%) | Â | Â | Â |
Intra-peritoneal infections | 74 (40.7) | 59 (41.0) | 15 (39.5) |
Intra-peritoneal infections after liver transplantation | 13 (7.1) | 4 (2.8) | 9 (23.7) |
Urinary tract infections | 29 (15.9) | 29 (20.1) | 0 (0.0) |
Febrile neutropenia | 16 (8.8) | 11 (7.6) | 5 (13.2) |
Bone and soft-tissue infections | 17 (9.3) | 14 (9.7) | 3 (7.9) |
Blood stream infections | 20 (11.0) | 15 (10.4) | 5 (13.2) |
Pulmonary infections | 10 (5.5) | 10 (6.9) | 0 (0.0) |
Vascular grafts infections | 3 (1.6) | 2 (1.4) | 1 (2.6) |
Comorbidity n, (%) | Â | Â | Â |
Cancer and hematologic malignancy | 65 (35.7) | 57 (39.6) | 8 (21.1) |
Hematologic malignancy | 22 (12.1) | 14 (9.7) | 8 (21.1) |
Solid organ transplantation | 19 (10.4) | 10 (6.9) | 9 (23.7) |
Bone marrow and stem cell transplantation | 9 (4.9) | 3 (2.1) | 6 (15.8) |
Diabetes mellitus | 14 (7.7) | 12 (8.3) | 2 (5.3) |
Collagen vascular disease | 12 (6.6) | 9 (6.3) | 3 (7.9) |
Chronic kidney disease | 53 (29.1) | 40 (27.8) | 13 (34.2) |
Structural abnormality of urinary tract | 22 (12.1) | 21 (14.6) | 1 (2.6) |
Hemodialysis | 12 (6.6) | 10 (6.9) | 2 (5.3) |
Antimicrobial therapy n, (%) | Â | Â | Â |
Vancomycin | 48 (26.4) | 26 (18.1) | 22 (57.9) |
Linezolid | 13 (7.1) | 3 (2.1) | 8 (21.1) |
Teicoplanin | 14 (7.7) | 6 (4.2) | 8 (21.1) |
Meropenem | 37 (20.3) | 37 (25.7) | 0 (0.0) |
Imipenem/cilastatin | 15 (8.2) | 15 (10.4) | 0 (0.0) |
Biapenem | 2 (1.1) | 2 (1.4) | 0 (0.0) |
Doripenem | 9 (4.9) | 9 (6.3) | 0 (0.0) |
Piperacillin | 10 (5.5) | 10 (6.9) | 0 (0.0) |
Tazobactam/piperacillin | 18 (9.9) | 18 (12.5) | 0 (0.0) |
Ampicillin | 2 (1.1) | 2 (1.4) | 0 (0.0) |
Sulbactam/ampicillin | 6 (3.3) | 6 (4.2) | 0 (0.0) |
Levofloxacin | 21 (11.5) | 21 (14.6) | 0 (0.0) |
Ciprofloxacin | 3 (1.6) | 3 (2.1) | 0 (0.0) |
Tosufloxacin | 1 (0.5) | 1 (0.7) | 0 (0.0) |
Combination therapy | 18 (9.9) | 18 (12.5) | 0 (0.0) |
Culture-positive specimens n, (%) | Â | Â | Â |
Urine | 32 (17.6) | 27 (18.8) | 1 (2.6) |
Sputum | 9 (4.9) | 9 (6.3) | 0 (0.0) |
Blood | 37 (20.3) | 25 (17.4) | 6 (15.8) |
Peritoneal fluid | 32(17.6) | 24 (16.7) | 8 (21.1) |
Pleural fluid | 1 (0.5) | 1 (0.7) | 0 (0.0) |
Bile | 16 (8.8) | 10 (6.9) | 6 (15.8) |
Discharge from abscess | 45(24.7) | 37 (25.7) | 8 (21.1) |
Central venous catheter tip | 4 (2.2) | 4 (2.8) | 0 (0.0) |
Throat swab | 5 (2.7) | 4 (2.8) | 1 (2.6) |
Vascular graft | 3 (1.6) | 2 (1.4) | 1 (2.6) |
Polymicrobial culture | 83 (45.6) | 70 (48.6) | 13 (34.2) |